A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) (NCT06581198)
A Phase 2, Open-label, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel in Patients With Active, Refractory Systemic Lupus Erythematosus (SLE) or Active, Refractory Lupus Nephritis (LN).
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).
Who can join: Review the eligibility criteria below.
Location: University Of Alabama — Birmingham, Alabama
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (101 Sites)
Showing the first 25 of 101 sites.
- University Of Alabama — Birmingham, Alabama
- Loma Linda University — San Bernardino, California
- UCSF — San Francisco, California
- UCSF — San Francisco, California
- Sutter Health Network — San Pablo, California
- Ann and Robert H Lurie Childs Hosp — Chicago, Illinois
- Northwestern University — Chicago, Illinois
- University Of Iowa — Iowa City, Iowa
- University of Kentucky — Lexington, Kentucky
- Tufts Medical Center — Boston, Massachusetts
- Boston Medical Center — Boston, Massachusetts
- WA Uni School Of Med — St Louis, Missouri
- Duke Clinical Research Institute — Durham, North Carolina
- Oregon Health Sciences University — Portland, Oregon
- Houston Methodist Hospital — Houston, Texas
- Univ Of TX MD Anderson CC — Houston, Texas
- University of Texas MD Anderson Cancer Center — Houston, Texas
- LDS Hospital — Salt Lake City, Utah
- LDS Hospital — Salt Lake City, Utah
- Novartis Investigative Site — Clayton, Victoria
- Novartis Investigative Site — Graz,
- Novartis Investigative Site — Vienna,
- Novartis Investigative Site — Salvador, Estado de Bahia
- Novartis Investigative Site — Barretos, São Paulo
- Novartis Investigative Site — São Paulo, São Paulo
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lupus Erythematosus, Systemic
- A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) — Phoenix, Arizona
- Interactive Digital Technology to Assess and Improve Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus — Denver, Colorado
- A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus — Homewood, Alabama
- Engagement in CHildhood-Onset Systemic Lupus — The Bronx, New York
- A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus — Huntington Park, California
- A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus — Tucson, Arizona
Explore by condition: All Lupus Erythematosus, Systemic clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.